Zobrazeno 1 - 10
of 643
pro vyhledávání: ''
Autor:
Chiara Giacomelli, Astrid Wachter, Stefan Wiemann, Jung J, Yosef Yarden, Cindy Körner, Ozgur Sahin, Stefan Uhlmann, Rainer Will, Ulrike Korf, Ibing S, Tim Beißbarth, Heiko Mannsperger
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-19 (2021)
BMC Cancer
BMC Cancer
Background Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC). Treatment options for TNBC patients are limited and further insights into disease aetiology are needed to develop better therapeutic approaches. mic
Autor:
Ryne C. Ramaker, Richard M. Myers, Emily R Gordon, Andrew A. Hardigan, Sara J. Cooper, Carter A. Wright
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Pancreatic ductal adenocarcinoma (PDAC) patients suffer poor outcomes, including a five-year survival of below 10%. Poor outcomes result in part from therapeutic resistance that limits the impact of cytotoxic first-line therapy. Novel ther
Autor:
Jacqueline H. Law, Sai W. Tsao, Mona Teng, Fei-Fei Liu, Valentin Petit, Jeff Bruce, Wei Shi, Pierre-Antoine Bissey, Kenneth W. Yip
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
BMC Cancer
BMC Cancer
Background A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signatur
Autor:
Claire F. Verschraegen, Daniel Spakowicz, David P. Carbone, Carolyn J Presley, Abdul Miah, Gabriel Tinoco, Jarred Burkart, Dwight H. Owen, Rebecca Hoyd, Madison Grogan, James S. Bassett, Lang Li, Kari Kendra, Sandip H. Patel, Lei Wang, Mitchell Muniak, Gregory A. Otterson, Mingjia Li, Marium Husain, Andrew Johns
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
BMC Cancer
BMC Cancer
Background The microbiome has been shown to affect the response to Immune Checkpoint Inhibitors (ICIs) in a small number of cancers and in preclinical models. Here, we sought to broadly survey cancers to identify those in which the microbiome may pla
Autor:
Vanessa Anunobi, Monica Bautista, Kelly Daescu, Nikki A. Delk, Rachel Meade, Haley Dahl, Chao Xing, Felix Bayerl, Ally Wong, Nisha Ghatwai, Ragini Mistry, Mohammed Kanchwala, Afshan Fathima Nawas, Shayna E. Thomas-Jardin
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Background Breast (BCa) and prostate (PCa) cancers are hormone receptor (HR)-driven cancers. Thus, BCa and PCa patients are given therapies that reduce hormone levels or directly block HR activity; but most patients eventually develop treatment resis
Autor:
Xiaotao Zhang, Pablo C. Okhuysen, Paul Scheet, Wesley Siu, Gladys Browman, Carrie R. Daniel, Joseph F. Petrosino, Scott Kopetz, Karen Basen-Engquist, Kristi L. Hoffman, Samir M. Hanash
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
BMC Cancer
BMC Cancer
BackgroundMouse and human studies support the promise of dry beans to improve metabolic health and to lower cancer risk. In overweight/obese patients with a history of colorectal polyps or cancer, the Beans to Enrich the Gut microbiome vs. Obesity’
Autor:
Emerson Y. Chen, Vinay Prasad, Talal Hilal, Myung S. Kim, Jennifer Gill, Tyler Crain, Alyson Haslam, Diana Herrera-Perez
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer
BMC Cancer
Background Identifying ineffective practices that have been used in oncology is important in reducing wasted resources and harm. We sought to examine the prevalence of practices that are being used but have been shown in RCTs to be ineffective (medic
Autor:
Xiaoyan Zhou, Xichun Hu, Yaohui Wang, Silong Hu, Yilin Shao, Yifeng Hou, Qifeng Wang, Yingjian Zhang, Yan-Li Wang, Xin Liu, Wentao Li, Zhiguo Luo, Yong Chen
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Background Sentinel lymph node is the first stop of lymphatic spreading of cancer with known primary. The lymph node metastasis pattern of cancer of unknown primary (CUP) is unclear and has been presumed to follow the same pathway. To test this hypot
Autor:
Jagesh V. Shah, Scott E. Schaus, Hyunjin Shin, Chandra Sekhar Pedamallu, Patrick Stoiber, Hang Gyeong Chin, Jennifer L.S. Willoughby, Mark P. Roberto, Kelly George, Ulla Hansen, Kevin Fitzgerald
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
BMC Cancer
BMC Cancer
Background The oncogene LSF (encoded by TFCP2) has been proposed as a novel therapeutic target for multiple cancers. LSF overexpression in patient tumors correlates with poor prognosis in particular for both hepatocellular carcinoma and colorectal ca
Autor:
Gabriella Pittau, Pamela Biondani, Wathek Almohamad, Ayhan Ulusakarya, Abdoulaye Karaboué, Oriana Ciacio, Mazen Haydar, Yusuf Gumus, Amale Chebib, Pasquale F. Innominato
Publikováno v:
BMC Cancer
BMC Cancer, BioMed Central, 2020, 20 (1), pp.515. ⟨10.1186/s12885-020-07004-y⟩
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Cancer, BioMed Central, 2020, 20 (1), pp.515. ⟨10.1186/s12885-020-07004-y⟩
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Background FOLFIRINOX is a pillar first-line regimen in the treatment of pancreatic cancer. Historically, biliary tract cancer (BTC) and pancreatic cancer have been treated similarly with gemcitabine alone or combined with a platinum compound. With g